Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.

Published

Journal Article (Review)

INTRODUCTION: Hospital-acquired pneumonia is a common infection, associated with substantial mortality. Despite the increasing prevalence of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA), approved treatment options for this pathogen are limited. AREAS COVERED: This article reviews the pharmacokinetics, dosing, preclinical studies and clinical efficacy, and safety of telavancin, with a particular focus on results from trials in nosocomial pneumonia. PubMed and Congress websites were searched for relevant articles published between 2003 and 2010. EXPERT OPINION: Telavancin is a lipoglycopeptide antibiotic with rapid, bactericidal activity against MRSA, and may provide another option for the treatment of nosocomial pneumonia, owing to Gram-positive pathogens.

Full Text

Duke Authors

Cited Authors

  • Rubinstein, E; Corey, GR; Stryjewski, ME; Kanafani, ZA

Published Date

  • December 2011

Published In

Volume / Issue

  • 12 / 17

Start / End Page

  • 2737 - 2750

PubMed ID

  • 22077833

Pubmed Central ID

  • 22077833

Electronic International Standard Serial Number (EISSN)

  • 1744-7666

Digital Object Identifier (DOI)

  • 10.1517/14656566.2011.633511

Language

  • eng

Conference Location

  • England